Group 1 - The forum held on November 18 in Wuxi attracted over 700 guests, including executives from more than 30 Fortune 500 companies, focusing on key industries like new energy and biomedicine [1] - A total of 21 high-level R&D projects were signed at the event, alongside the launch of two major industry platforms: the Jiangsu Province Biomedicine Full Industry Chain Open Innovation Alliance and the Jiangsu Province New Energy Industry Chain Hub Platform [1][6] - Jiangsu's actual foreign investment reached $103.74 billion from 2021 to 2024, with a national share of 16.4% in 2024, increasing to 18.1% in the first three quarters of this year [2] Group 2 - The Jiangsu Free Trade Zone's biomedicine open innovation development plan was approved, making it the first province in China to pilot in this field, featuring 18 policy measures and 77 specific tasks [3] - The plan aims to create a "highway" for the entire process of drug development, manufacturing, circulation, and use, with significant cost savings and faster customs clearance [3] - The presence of over 40% of Apple's core suppliers in China, with half located in Jiangsu, highlights the region's mature industrial chain [4] Group 3 - Pfizer announced the launch of the "Pfizer-Jiangsu Full Industry Chain Innovation Empowerment Plan" to deepen its involvement in Jiangsu's biomedicine sector [5] - LG Group has invested nearly $10 billion in Jiangsu, viewing it as a key base for new energy battery production, with plans for further investment in new technologies [5] - The establishment of two major industry platforms aims to enhance collaborative efficiency and international competitiveness in key sectors like power batteries and renewable energy [6] Group 4 - Eli Lilly plans to deepen local cooperation in major disease areas, having invested a total of $15 billion in its Suzhou pharmaceutical production base over the past 30 years [7]

Core Insights - The forum held on November 18 in Wuxi focused on international cooperation in supply chains, attracting over 700 attendees, including executives from more than 30 Fortune 500 companies [1] - Key discussions revolved around the collaborative development of supply chains in critical industries such as renewable energy and biomedicine, leading to the signing of 21 high-level R&D projects [1][6] - Jiangsu province has achieved significant foreign investment, with actual foreign capital usage reaching $103.74 billion from 2021 to 2024, accounting for 16.4% of the national total in 2024 [2] Industry Developments - The establishment of the "Jiangsu Province Biomedicine Full Industry Chain Open Innovation Alliance" and the "Jiangsu Province New Energy Industry Chain Hub Platform" aims to enhance global resource connectivity and build a new industrial ecosystem [1][6] - The "Jiangsu Free Trade Zone Biomedicine Full Industry Chain Open Innovation Development Plan" has been approved, making Jiangsu the first province in China to pilot in the biomedicine sector, featuring 18 policy measures to streamline the R&D process [3] Company Engagements - GE Healthcare's Wuxi base has become the largest ultrasound equipment center globally, supporting over 460 upstream and downstream suppliers, showcasing the strength of the industrial cluster [2] - Pfizer announced the launch of the "Pfizer-Jiangsu Full Industry Chain Innovation Empowerment Plan" to deepen its involvement in Jiangsu's biomedicine sector, emphasizing local production and global market integration [5][7] - Apple’s core suppliers, over 80% of whom have factories in China, with half located in Jiangsu, highlight the region's mature industrial chain and advancements in smart manufacturing and green transformation [4]